GlassScriptPhysician profile
Henry K Prince
NPI 1518043173
$2,797.11
in general payments reported to CMS, 2019-2025
25 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $1,855 · 2022: $130 · 2023: $282 · 2024: $204 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dr.Reddy'S Laboratories,INC. | $1,800.00 | 2020 | |
| Hologic Sales and Service, LLC | $176.18 | 2023-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Thinprep 2000 Processor |
| Coopersurgical, INC. | $81.63 | 2022-2025 | Paragard T 380a |
| Evofem Biosciences, INC. | $77.59 | 2022-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $67.51 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $62.39 | 2023-2024 | Veozah |
| Abbvie INC. | $59.62 | 2022 | |
| Channel Medsystems, INC. | $46.24 | 2023 | |
| Agile Therapeutics, INC. | $41.41 | 2023-2024 | Twirla |
| Boston Scientific Corporation | $41.09 | 2019 | |
| Exeltis, USA INC. | $40.23 | 2019-2023 | Slynd |
| Organon LLC | $36.44 | 2024-2025 | Nexplanon |
| Lupin INC. | $31.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.42 | 2022 | |
| Optumhealth Care Solutions, LLC | $28.77 | 2023 | Vivify Health Care Team Portal, Zyno Solutions |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $25.65 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.25 | 2023 | |
| Smith+Nephew, INC. | $22.75 | 2020 | |
| Sumitomo Pharma America, INC. | $20.26 | 2024 | Myfembree |
| Allergan, INC. | $19.26 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.61 | 2019 | |
| Aspira Women'S Health INC | $16.66 | 2020 | |
| Therapeuticsmd, INC. | $15.00 | 2019 | |
| Pfizer INC. | $14.92 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.